Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.

Key facts

Study ID

NCT02719613

Run by

Bristol-Myers Squibb

People needed

67

Starts

2016-07-15

Expected to finish

2026-02-23

Last updated by the study team

2026-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participated in a previous elotuzumab protocol (including, but not limited to HuLuc63-1703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol
• Receiving elotuzumab and/or other study drugs at the time of signature of informed consent
• Males and Females, ages 18 and older

You may not qualify if…

• All participants previously discontinued from an elotuzumab study for any reason
• Participants not receiving clinical benefit from previous study therapy
• Participants who are not medically well enough to receive study therapy as determined by the investigator
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Local Institution - 0020 — Tucson, Arizona, United States
• Local Institution - 0017 — Bakersfield, California, United States
• Local Institution - 0022 — Fountain Valley, California, United States
• Local Institution - 0016 — West Hollywood, California, United States
• Local Institution - 0019 — Denver, Colorado, United States
• Local Institution - 0021 — Jacksonville, Florida, United States
• Local Institution - 0042 — St. Petersburg, Florida, United States
• Local Institution - 0009 — Atlanta, Georgia, United States
• Local Institution - 0003 — Indianapolis, Indiana, United States
• Local Institution - 0002 — Boston, Massachusetts, United States
• Local Institution - 0008 — St Louis, Missouri, United States
• Local Institution - 0004 — New York, New York, United States
• Local Institution - 0001 — Bethlehem, Pennsylvania, United States
• Local Institution - 0018 — Dallas, Texas, United States
• Local Institution - 0034 — Heidelberg, Victoria, Australia
• Local Institution - 0023 — Antwerp, Belgium
• Local Institution - 0011 — Toronto, Ontario, Canada
• Local Institution - 0010 — Halifax, Canada
• Local Institution - 0035 — Athens, Greece
• Local Institution - 0036 — Budapest, Hungary
• Local Institution - 0015 — Ancona, Italy
• Local Institution - 0012 — Florence, Italy
• Local Institution - 0013 — Genova, Italy
• Local Institution - 0043 — Ravenna, Italy
• Local Institution - 0044 — Terni, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.